ArticleBMC infectious diseases2026
Genomic surveillance of H1N1, H3N2 and influenza B Victoria lineage viruses in Qingyang (2020-2023): phylogenetic and molecular characteristics analysis of HA/NA genes.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHA and NA are important surface proteins of influenza viruses. The purpose of this study was to explore the molecular evolution and amino acid mutations of HA and NA of H1N1, H3N2 and Influenza B Victoria lineage (B/Victoria) viruses in Qingyang from 2020 to 2023.
methodsThrough the China Influenza Surveillance Information System, the positive data of influenza etiology surveillance in Qingyang from 2020 to 2023 were screened. A total of 19 samples of H1N1, 47 samples of H3N2 and 51 samples of B/Victoria were screened. Subsequently, virus nucleic acid extraction, whole genome sequencing, amino acid and nucleotide homology analysis, phylogenetic analysis, and amino acid site mutation analysis were performed.
resultsMiniseq sequencing was performed on 117 influenza strains. Homology analysis showed that H1N1 and H3N2 strains had relatively low homology with vaccine representative strains. Amino acid mutation analysis of HA and NA showed that the H1N1 strains had receptor binding site and antigen site mutations, but no glycosylation site and resistance site mutations. However, H3N2 strains had mutations at receptor binding sites, antigenic sites, glycosylation sites, and resistance sites. The B/Victoria strains had antigenic site mutations, but no drug resistance site mutations. Moreover, only strains from 2021 to 2022 exhibit a glycosylation site mutation.
conclusionGenetic characteristics analysis was conducted for the first time on H1N1, H3N2, and B/Victoria viruses prevalent in Qingyang, which enables us to understand the molecular evolution and amino acid mutations of HA and NA. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.